ALK and inflammatory myofibroblastic tumor: Both studies support all the case reports describing responses in ALK-positive IMT patients treated with crizotinib, as described in the review from Theilen et al. In this review, various case reports showed a complete response (CR), others only partial response (PR) or stable disease (SD) [31].